Brief: Royalty Pharma Q3 Net Income USD 122 Million
08/11/2023 12:00
Nov 08 (Reuters) - Royalty Pharma Q3 adjusted EBITDA USD 582 million. * Q3 operating expenses USD 385 million * Q3 pretax profit USD 122 million * Q3 operating income USD 151 million
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)